- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Medicare Part D Cost Strategy; Drug Pricing Not in Budget Deal; Norovirus at Olympics
President Trump will reportedly unveil a Medicare Part D cost strategy next week; a bipartisan drug pricing measure was left out of the budget deal; hand sanitizer is popping up all over the Winter Olympics in South Korea in an effort to fight back against a norovirus outbreak.
Trump Reportedly to Unveil Medicare Part D Cost Strategy Next Week
President Donald Trump will propose lowering prescription drug costs for Medicare Part D by allowing beneficiaries to share in rebates that drug companies pay to insurers and pharmacy benefit managers, an administration official told the Associated Press. The White House will release its 2019 budget plan next week.
Bipartisan Drug Pricing Bill Left Out of Budget Deal
A bipartisan drug pricing measure was left out of the budget deal signed by Trump on Friday morning, The Hill reports. The bill would keep branded drug companies from using delay tactics to prevent cheaper generic competitors from coming onto the market. Drug pricing advocates blamed the bill's omission from the budget deal on the pharmaceutical industry, which had lobbied hard against the measure.
Hand Sanitizer Used to Combat Winter Olympics Norovirus Outbreak
A required item at the Winter Olympics, according to The New York Times, are bottles and bottles of 62% ethanol hand sanitizer. An outbreak of norovirus in Pyeongchang, South Korea, has infected 128 so far. Anyone entering the cafeteria in the athletes’ village is required to use sanitizer before going to the buffet, the paper reported.
Health Equity and Access Weekly Roundup: December 9, 2023
December 9th 2023The Center on Health Equity and Access provides information on the latest news, research discoveries, and initiatives dedicated to addressing healthcare disparities and improving overall access to high-quality care.
Read More
New TROPiCS-02 Data Back Sacituzumab Govitecan for Older Patients With Breast Cancer
December 9th 2023This phase 3 study investigated sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, vs treatment of physician’s choice in pretreated patients who have endocrine-resistant hormone receptor–positive/HER2-negative breast cancer, the most common form of breast cancer.
Read More
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
